Renovos offers unique bone marrow mesenchymal stem cells (MSC), which have been isolated from patients with osteoarthritis for research purposes.
MSCs, or skeletal stem cells of bone marrow origin, have been used as research tools for decades and within the past 10 years progressed to hundreds of clinical trials for various regenerative and immunomodulatory approaches.
The MSC research field is expanding rapidly, however, the outcomes of various in-vitro and in-vivo studies are not directly comparable due to variability in the stem cell source used, purity, or even irrelevant donor selection.
By applying clonal culture techniques, Renovos MSCs are supplied at the highest purity and at an early passage, allowing for cell expansion.
Renovos stem cells offer the following key advantages:
- Clinically relevant age range for testing therapeutics/biomaterials designed for the elderly, adults or adolescents
- Donors with clinical presentations -osteoarthritis; as a suitable model for relevant drug/biomaterial testing
- Early passages and guaranteed cell expansion – P2 stocks, >10 population doublings under optimal conditions
- Detailed flow cytometric analysis – for expression of common mesenchymal stem/progenitor cell markers, including for STRO-1, CD73, CD90, CD105
- Multipotency – tested for osteo, chondro and adipogenic differentiation in-vitro
- Pathogen-free (HBV/HCV/HIV, bacteria, mycoplasma and fungi)
- Various levels of purity of the stem cell populations available upon request: unselected mesenchymal, STRO-1 cell-enriched, Clonal
- Inventory available upon request, detailing lot availability, donor age and sex. Lot specific Certificate of Analysis are also available to view.
Currently, the following products are available:
- Bone Marrow Mesenchymal Stem Cells – Osteoarthritic, 500,000 Cells
Product Code: REN-OA-500
Disease State: Osteoarthritic - Bone Marrow Mesenchymal Stem Cells – Osteoarthritic, 1 million Cells
Product Code: REN-OA-1M
Disease State: Osteoarthritic
Please do contact Caltag Medsystems if you require MSCs from an alternate disease state, as the company may be able to provide a custom product.
